

SCHEDULE

PART I

CONTROLLED DRUGS TO WHICH SECTION 7(4) OF THE MISUSE OF DRUGS ACT 1971 APPLIES

1. The following substances and products, namely:—

-
- | | |
|---|---|
| (a) Bufotenine | Mescaline |
| Cannabinol | Methcathinone |
| Cannabinol derivatives not being
dronabinol or its stereoisomers | Psilocin |
| | Raw opium |
| Cannabis | Rolicyclidine |
| Cannabis resin | Tenocyclidine |
| Cathinone | 4-Bromo-2,5-dimethoxy- α -
methylphenethylamine |
| Coca leaf | |
| Concentrate of poppy-straw | <i>N,N</i> -Diethyltryptamine |
| Eticyclidine | <i>N,N</i> -Dimethyltryptamine |
| Etryptamine | 2,5-Dimethoxy- α ,4-dimethyl-
phenethylamine |
| Lysergamide | |
| Lysergide and other <i>N</i> -alkyl derivatives of
lysergamide | <i>N</i> -Hydroxy-tenamphetamine |
| | 4-Methyl-aminorex; |
-
- (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- (c) the following phenethylamine derivatives, namely—
- Allyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 - 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
 - 2-Amino-1-(3,4-dimethoxyphenyl)ethanol
 - Benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 - 4-Bromo- β ,2,5-trimethoxyphenethylamine
 - N*-(4-*sec*-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
 - Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 - 2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)ethylamine
 - 2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)-1-methylethylamine
 - 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

2-(1,4-Dimethoxy-2-naphthyl)ethylamine
 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethylamine
 α,α -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
 Dimethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
 4-Iodo-2,5-dimethoxy- α -methylphenethyl(dimethyl)amine
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 2-Methoxyethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 β -Methoxy-3,4-methylenedioxyphenethylamine
 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
 2-(α -Methyl-3,4-methylenedioxyphenethylamino)ethanol
 α -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-*N*-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-*N*-(α -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 α -Methyl-4-(methylthio)phenethylamine
 $\beta,3,4,5$ -Tetramethoxyphenethylamine
 $\beta,2,5$ -Trimethoxy-4-methylphenethylamine;

- (d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α -methylphenethylamine, an *N*-alkyl- α -methylphenethylamine, α -ethylphenethylamine, or an *N*-alkyl- α -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (e) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say—
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

- (v) by substitution at the 4-position of the piperidine ring with any alkoxy carbonyl or alkoxyalkyl or acyloxy group;
- (vi) by replacement of the *N*-propionyl group by another acyl group;
- (f) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from pethidine by modification in any of the following ways, that is to say—
 - (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an *N*-oxide or of a quaternary base.
- 2. Any stereoisomeric form of a substance specified in paragraph 1 above.
- 3. Any ester or ether of a substance specified in paragraph 1 or 2 above.
- 4. Any salt of a substance specified in any of paragraphs 1 to 3 above.
- 5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 above.